Patient's Query
Hi doctor,
My mother is currently undergoing treatment for advanced breast cancer, and her oncologist has mentioned Tukysa as a potential addition to her regimen.
Can you explain how Tukysa differs from other medications for advanced breast cancer and what factors contribute to its suitability for individuals in her situation?
Please help.
Thank you.
Hi,
Welcome to icliniq.com.
I read your query and understand your concern.
Tukysa (Tucatinib) is a tyrosine kinase inhibitor of HER2 (a protein that causes cancer to grow fast). In vitro, Tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK (mitogen-activated protein kinase) and AKT (protein kinase B) signaling and cell proliferation, and shows anti-tumor activity in HER2-expressing tumor cells.
Tuksya is a smaller molecule than Trastuzumab, so it can target the part of HER2 on the inside of cancer cells. In this way, TUKYSA and Trastuzumab work together to completely block the HER2 activity that promotes the growth of cancer.
In a concise form, it disrupts the internal signaling pathway of the tumor cells and prevents tumor cell proliferation. Every medication has its own mechanism of action, and depending on the tumor type and synergistic mechanisms of medicines, these are advised as part of treatment.
Most of these medications are standard treatment for neoplasms, and a standard regimen is followed almost all over the world. So I would suggest trusting your mother's treatment and instilling the same in her.
I hope this information will help you.
Thank you.
Was this conversation helpful?
Answered byDr. Sukhdev Garg
Medically reviewed byiCliniq medical review team
Same symptoms don't mean you have the same problem. Consult a doctor now!
Related Questions
Fruquintinib - A Comprehensive Review
Ceruminal Gland Neoplasm - Causes, Symptoms, Diagnosis, and Treatment
Breast Cancer - Causes, Symptoms, Types, Risk Factors, Diagnosis, Treatment, and Precautions
Plasma Cell Neoplasm - Overview
Breast Cancer and Hormonal Birth Control: Is There a Risk?
Bosutinib Breakthrough: A New Hope for Chronic Myelogenous Leukemia
Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.